Ladenburg initiated coverage of Marker Therapeutics with a Buy rating and $11 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRKR:
- Marker Therapeutics’ MT-601 Shows Promising Results
- Marker Therapeutics announces presentation on Phase 1 APOLLO study
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
- Marker Therapeutics Advances in Immuno-Oncology
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results